Eckert & Ziegler SE: A Better Business, Not Yet a Better Price

That origin shaped the company's path in two ways. First, it made regulation an ingredient of the business model rather than an external obstacle. Second, it predisposed management to think like consolidators. The history page is essentially a long list of adjacent acquisitions: Isotope Products Laboratories in California, DuPont's worldwide sources business, CIS bio's radiation equipment division, Nuclitec in Braunschweig, f-con Europe, Euro-PET, areas of Gamma-Service, BioScan's equipment business, Brazilian operations, and several brachytherapy and instrumentation assets. This is not a company that discovered growth by making an app. It compounded by buying hard-to-handle niche assets, integrating them, and building a regulatory and logistics spine around them.

The first stage of the modern story ran from founding through the early 2000s: a holding company assembling isotope-related industrial and medical assets fast enough to justify a public listing. At IPO, the market could reasonably read the company as a specialist industrial-medical roll-up. The strategic choice was to aggregate licensed activities that were too small or awkward for larger corporates but collectively meaningful. The benefit of that path was obvious: once a company learns how to handle radioactive materials across jurisdictions, it can add adjacent products faster than a newcomer can clear the first regulatory gate. The lasting impact of that phase is still visible in today's Isotope Products segment and in the group's multinational handling and transport permits.

The second stage ran roughly from the mid-2000s through 2020 and was about portfolio breadth, internationalization, and the slow sorting of businesses that looked related on paper but had very different economics. During this period the company expanded into radiopharmaceutical services, PET-related activities, brachytherapy accessories, industrial sources, and measurement technologies, while also building positions in Brazil, Argentina, China, the Czech Republic, and North America. The business model still looked diverse, but one internal truth was emerging: the market would eventually reward recurring radiopharma-adjacent activities more than device-heavy or lower-growth therapy equipment lines. That is why the 2021 divestment of the HDR tumor irradiation business matters. Management was not abandoning radiation therapy altogether; it was exiting a chunk of the portfolio that diluted capital-market clarity and consumed attention.

The third stage began around 2021 and is the one that matters most for today's shareholders. The 2021 annual report describes a "miraculous glut of cash" driven by surging demand for pharmaceutical radioisotopes, services and equipment for radiopharmaceutical manufacturing from late 2018 onward, accelerated by acquisitions and financing rounds across the radiopharma industry. That language is unusually candid and important. Management was saying that a decades-old company had suddenly acquired a second, stronger growth logic. The group did not need to reinvent itself from scratch. It needed to redirect capital and simplify its shape around the parts of the business where radiopharmaceutical demand was already paying.

Three turning points made that shift concrete. The first was divesting the HDR business in 2021, which reduced exposure to a weaker-fit asset and improved focus. The second was the tightening of isotope and radiopharma strategy from 2023 onward: environmental approval for the Jintan site, manufacturing authorization for GMP-grade lutetium-177, a growing list of supply and reservation agreements with pharma developers, and the decision in late 2023 to prepare the Pentixapharm split-off. The third was 2024–2026 infrastructure execution: opening the Ac-225 facility near Prague with UJF in June 2024, beginning actinium production in December 2024, scaling that effort in February 2026, opening the new Qi Kang isotope site in Jintan in June 2026, and using Berlin, Wilmington, Boston, Braunschweig, Dresden-Rossendorf and São Paulo as a network rather than isolated local assets.

The Pentixapharm episode deserves special treatment because it says a lot about management discipline. Eckert & Ziegler had acquired majority control of Pentixapharm in 2021, then used a spin-off in 2024 to separate the therapy developer from the isotope-services platform. The history page lists the 2024 spin-off as a milestone, and the 2025 annual report plus Q1 2026 report show that the relationship did not disappear; it changed form, with convertible-bond exposure and operational links still present. In plain English, management chose to stop asking public investors to underwrite a development-stage drug story inside the same quoted entity as the isotope-supply business. That was the right move. The market had begun valuing the group increasingly as infrastructure and supply-chain exposure, not as a clinical-development vehicle.

The leadership transition fits the same pattern. Dr. Harald Hasselmann, who had already been in the organization since 2015 and on the Executive Board since 2017, became CEO in June 2023. Dr. Gunnar Mann, an internal operator with a physics background and long company tenure, joined the Executive Board in January 2025. Frank Yeager's Executive Board term ended at the close of 2025, but he continued to run Isotope Products operationally. The company also reduced the Executive Board from three members to two for 2026. This was not a founder walk-away or a rescue reset. It was a simplification under executives who are more tightly tied to the current Medical-led strategy than to the old broader portfolio identity.

One historical note requires data hygiene. The company's 2025 capital increase from company funds and subsequent bonus-share stock split tripled the number of shares from 21,171,932 to 63,515,796. The 2025 annual report explicitly says prior-year per-share figures were restated for the August 2025 split, and the Q1 2026 report states the same. This report therefore uses split-adjusted per-share data throughout unless the source itself clearly predates adjustment, which keeps price, EPS and dividend comparisons consistent across the period.

The company that emerged from these stages has a much clearer identity than the one that went public. It is still a real manufacturer and handler of radioactive materials, with all the complexity that implies. It is also now a supplier to one of the most capacity-constrained and regulation-heavy areas of oncology. That shift did not happen by miracle. It happened because a long-accumulated capability suddenly became valuable to a larger industry wave.

Financial vertical review

The five-year numbers tell a clean story. Revenue rose from €180.4 million in 2021 to €222.3 million in 2022, €246.1 million in 2023, €295.8 million in 2024, and €312.0 million in 2025. EBIT moved from €47.4 million in 2021 to €44.5 million in 2022, €45.5 million in 2023, €59.9 million in 2024, and €73.7 million in 2025; adjusted EBIT reached €77.7 million in 2025. Net profit after taxes and minorities went from €34.5 million in 2021 to €29.3 million in 2022, €26.3 million in 2023, €33.3 million in 2024, and €48.8 million in 2025. In other words, the group grew revenue almost every year, but earnings quality improved in two distinct waves: first in 2021 as radiopharma demand hit, then again in 2024–2025 as the Medical segment's mix improved and a cleaner portfolio structure took hold.

What drove revenue was not one lever. In 2022 and 2023 the company was still digesting strategic repositioning while growing through stronger isotope demand and a rising Medical mix. By 2024 and 2025 the pattern was much clearer: management explicitly credited pharmaceutical radioisotopes, generators, licensing income, and CDMO-related activity inside Medical. The 2025 annual report says the Medical segment's pharmaceutical radioisotope business remained the primary driver, with generators, license business and CDMO activity especially important. That is different from simple volume growth. It is mix improvement toward higher-value revenue.

Margins reveal why the market lost interest in treating Eckert & Ziegler as a plain industrial stock. EBIT margin was 26% in 2021, then compressed to 20% in 2022 and 18% in 2023 as the company absorbed investments, portfolio movements and a less favorable profit mix. It then recovered to 20% in 2024 and 24% in 2025, while adjusted EBIT margin moved from 22% in 2024 to 25% in 2025. Medical gross margin in 2025 reached 49%, and management tied that directly to high-margin generators and license revenue. That is exactly the kind of source-specific margin lift investors should care about: not vague "efficiency," but more profit-rich products inside the segment that matters most.

Cash conversion has been good over a cycle, though not perfectly smooth quarter to quarter. Operating cash flow over 2021–2025 was €33.9 million, €34.3 million, €45.2 million, €84.0 million and €58.4 million. Against net profit after minorities of €34.5 million, €29.3 million, €26.3 million, €33.3 million and €48.8 million, the five-year operating-cash-flow-to-net-income ratio averaged about 1.5x. That is strong. The caveat is 2025, when operating cash flow fell despite stronger earnings, because receivables rose, payables fell, customer advances declined, and inventories were built up for anticipated demand. The company remains a cash generator. It is just not a frictionless one. Working capital matters.

The balance sheet is a real strength. Net financial position improved from €87.9 million in 2021 to €60.3 million in 2022, €41.6 million in 2023, €98.0 million in 2024, and €115.2 million in 2025. Q1 2026 still showed €123.8 million of cash and cash equivalents against €11.9 million of loan liabilities, with an equity ratio of 57%. That balance sheet does three jobs. It gives the company room to fund the expansion of isotope and CDMO infrastructure. It lowers the chance that a temporary customer or mix wobble creates a financing problem. And it means valuation should be thought about on an enterprise-value basis as much as on earnings multiples, because the cash pile is material relative to the equity value.

There is one balance-sheet feature investors should not ignore: radioactive-material businesses accumulate long-tail obligations that ordinary medtech firms do not. The 2025 annual report shows €44.0 million of non-current provisions for site restoration obligations and €34.7 million for disposal provisions. These are not new surprises; they are part of the business model. Still, they are a reminder that part of Eckert & Ziegler's moat comes with cleanup and compliance burdens that never fully disappear. The market should reward the licensing barrier but remember the tail.

Returns on capital have probably improved structurally, but the accounting path is messy enough that it is better to describe the direction than to force a false precision. Equity rose from €192.5 million in 2021 to €253.4 million in 2025 while net profit ended the period sharply higher than it began. The right interpretation is that returns were temporarily diluted during reinvestment and restructuring years, then re-expanded as higher-margin Medical activity scaled. That pattern fits the strategic transition better than any single one-year ROE figure.

Price and valuation history

The stock has moved through three broad market phases in the last five years. The first was a radiopharma-awakening re-rating in 2021. The 2021 annual report shows a 110% gain in the year-end closing price, and management's letter explicitly linked the cash surge and demand shock to an industry funding boom in radiopharmaceuticals. The second phase was digestion through 2022 and 2023: revenue kept growing, but EBIT and EPS softened, the company reworked its portfolio, and the market stopped paying peak excitement multiples for a business that was still investing and simplifying. The third phase came in 2024 and early 2025, when earnings accelerated, actinium and lutetium milestones stacked up, and the stock regained a thematic premium before cooling again into mid-2026.

The valuation labels changed with those phases. In 2021 the market treated Eckert & Ziegler almost like a scarce infrastructure play on an emerging oncology modality. In 2022–2023 it looked more like a good niche industrial-medical compounder whose revenue kept rising while earnings stalled. In 2024–2025 it moved back toward a specialty-growth label as investors saw proof that Medical could drive the group. By mid-2026 the label is mixed again. The headline P/E is around 18x on split-adjusted trailing EPS of roughly €0.79, the dividend yield is around 1.5%, and the stock is down sharply from its 52-week high. Those are not bubble numbers. They are also not distressed numbers. The market is no longer pre-paying an extreme radiopharma dream, but it still embeds some credit for higher-quality growth than the 2026 guidance alone would suggest.

The current valuation sits in a middle zone. Using the 2026-07-14 close of €14.43 and the Q1 2026 share count net of treasury shares, equity value is about €903 million. Against 2025 net financial position of €115.2 million and 2026 adjusted EBIT guidance of about €80 million, the stock trades at roughly 9.8x forward EV/adjusted EBIT. That is inexpensive compared with pure radiopharma-growth names, but it is also consistent with a company whose disclosed 2026 growth target is only about 3%. The multiple center shifted because the business got better, but part of the earlier premium was still market taste rather than just business quality.

Business model and moat

Eckert & Ziegler's business model is easiest to understand as a licensed handling-and-processing machine wrapped around isotope demand. The group does not need to own every upstream production step to make good money. It makes money because radioactive materials are hard to produce, harder to purify to pharmaceutical grade, harder still to move across borders, and difficult to integrate into regulated manufacturing flows. The latest segment disclosure makes that clear. Medical includes long-lived radioisotopes for pharma applications, early-development services for radiopharmaceutical products, radiosynthesis equipment, quality-control equipment, prostate seeds, therapeutic accessories, ophthalmological products, and other plant-engineering work. Isotope Products covers the legacy but durable franchise in industrial, imaging and calibration sources. The most profitable center is now Medical, not because it is larger by a huge margin, but because its mix is better.

That revenue structure matters more than the simple segment split. In 2025, Medical produced €171.0 million of external sales and €51.1 million of adjusted EBIT. Isotope Products produced €140.9 million of external sales and €28.3 million of adjusted EBIT. Medical therefore generated a much larger share of profit than of revenue. The annual report names the reasons: generator sales, license business and CDMO activity. This is the strongest evidence that Eckert & Ziegler is not merely riding a volume wave. It is moving into parts of the value chain where customers pay for documentation, validation, reliability, and regulatory readiness.

The cost structure produces some operating leverage, but not the pure kind software investors imagine. There are real fixed costs in facilities, radiation protection, quality systems, validation, licensing, and specialized personnel. There are also variable costs in radioisotope procurement, logistics, consumables, and product mix. When high-margin generator or license revenue rises, Medical margins move sharply, as 2025 proved. When the mix shifts the wrong way, as in Isotope Products in Q1 2026, margin slips quickly. This is a business with operating leverage, but the leverage comes from product mix and utilization of regulated capacity, not just from spreading SG&A.

The real moat starts with regulatory licenses and handling capability. Management states that the group holds the necessary permits for handling, storage and transport in pharmaceutical and technical radioisotopes, and operates facilities at several locations that perform the steps after actual isotope production, especially purification to GMP quality. That is not a marketing moat. It is a concrete barrier built over many years, and it is exactly the sort of capability a radiopharma developer often lacks. A biotech can design a promising molecule relatively quickly. It cannot quickly replicate a cross-border, GMP-ready isotope-processing, logistics and manufacturing network.

The second real moat is accumulated process know-how across adjacent niches. The history of acquisitions looks messy at first glance, but it created an unusually broad toolbox in isotopes, equipment, hot cells, sources, purification, and downstream manufacturing. That breadth is why the company can sign different types of agreements: raw isotope supply, purification support, CDMO services, radiosynthesis-related work, plant engineering, and even isotope-access agreements for emerging payloads such as lead-212. Competitors exist in each slice. Few listed companies occupy so many slices at once.

The third moat is customer stickiness created by regulatory dossier work and development timing. When Eckert & Ziegler supplies a generator, an isotope, or a manufacturing process for clinical work, the relationship is not as easily swappable as a normal reagent purchase. Customers can change suppliers, but not without regulatory, comparability, and timing costs. The company's public agreements with AtomVie, Bicycle, Actinium Pharmaceuticals and others are important less for their headline value, which is mostly undisclosed, than for what they say about where in the customer workflow the company is embedded. The same logic applies to Telix-related manufacturing and to the Jintan joint venture in China. Once you are part of the validated workflow, you are harder to dislodge than a casual component vendor.

The moat is not perfect. It is strongest in handling, purification, validation, and logistics. It is weaker in the sense that upstream isotope production itself can attract ambitious entrants, very large pharmaceutical companies can internalize more of the chain over time, and some contract economics can be competed away if capacity catches up to demand. The Financial Times piece on Eli Lilly's move into the nuclear-isotope business is a warning sign here: scarcity attracts capital. Radioisotope supply will not remain a gentleman's club forever. The reason that does not automatically break Eckert & Ziegler's position is that the company's moat is downstream-heavy and process-heavy, not solely based on owning a single rare reactor or cyclotron.

Management and governance are good but not pristine. Operationally, the company is run by insiders with relevant backgrounds: Harald Hasselmann has pharma experience and has been CEO since June 2023, while Gunnar Mann is a long-tenured operator with a physics background. The capital-allocation record of the last few years is mostly sensible: portfolio simplification, focused capacity investment, the Pentixapharm spin-off, and no reckless diversification despite management openly considering inorganic options. The 2025 letter to shareholders explicitly says acquisition only makes sense in special cases and that the company keeps its focus on isotopes. That is a sign of restraint.

The governance discount comes from control and related-party texture, not from a smoking gun. As of 2025 year-end, Supervisory Board chairman Dr. Andreas Eckert indirectly and directly controlled 31.16% of the share capital, and the company described him as the ultimate controlling party because in the past he indirectly held a majority of votes at annual meetings. The annual report also shows related-party leases through founder-connected vehicles and a consultancy arrangement for Jutta Ludwig after her move from the Executive Board to the Supervisory Board. The company says these were at arm's length; there is no disclosed accounting scandal or qualified audit opinion, and the auditor has been Forvis Mazars with unqualified opinions. Still, investors should apply some governance discount because influence is concentrated and family links exist on the supervisory side.

Industry and cycle

Eckert & Ziegler sits at the intersection of two industries that obey different rules. One is the old isotope-and-radiation supply chain: heavily regulated, specialized, slow-moving, and protected by licensing, logistics and safety requirements. The other is the newer radiopharmaceutical and radioligand-therapy wave in oncology: faster-growing, financed by large pharmaceutical interest, and increasingly constrained by isotope and manufacturing bottlenecks rather than by scientific imagination alone. The company matters because it can sell into both at once. Industrial and imaging-source demand makes the base business resilient. Radiopharma demand sets the growth rate.

The industry profit pool is not evenly distributed. The biggest drug companies capture the ultimate economics when a radioligand succeeds commercially: Novartis is the clearest public example, with approved radioligand products and a large oncology franchise. But upstream and midstream scarcity can also earn strong returns when supply is tight, which is why isotope access has become strategic. Reuters reported in 2024 that the European Commission cleared €2 billion of Dutch state aid for medical-isotope reactor capacity because shortages of essential isotopes are expected after 2030. The Financial Times separately reported that Eli Lilly moved into nuclear isotopes to secure actinium-225 access. When governments and pharma majors both worry about supply, the middle of the chain becomes valuable.

The cycle exposure is not mainly macroeconomic. This is not a rate-sensitive roll-up, nor a commodity producer in disguise. The relevant cycles are capacity-expansion cycles, product-mix cycles, policy cycles, and technology-adoption cycles inside nuclear medicine. In an upswing, the biggest beneficiary is Medical gross profit, because generators, licenses and CDMO work scale better than industrial-source volumes. In a downswing, the most fragile variable is margin mix, not group revenue: high-value medical lines can wobble quarter to quarter, and licensing revenue is explicitly unevenly distributed through the year. That makes reported earnings lumpy even when the structural story is intact.

Policy and regulation are permanent, not episodic. Every attractive part of the business depends on permits, radiation-protection rules, transport approvals, GMP compliance, and in some cases product registration by geography. The upside is that regulation keeps casual entrants out. The downside is that approvals can delay ramp-ups and site economics. Management has recently highlighted milestones such as Japanese approval for GalliaPharm and European approval for Theralugand. Those are commercially relevant because they turn technical capability into sellable product in specific markets. They also show why expansion is slower than investors sometimes hope. Radioactive products do not scale on a normal manufacturing timetable.

Geopolitics matters through logistics, sanctions, and localization of production. The company itself flags international trade and sanctions policy as a current challenge. Management's answer has been to build at multiple sites and distribute locally or regionally where possible. Berlin-Buch, Braunschweig, Dresden-Rossendorf, Řež, Wilmington, Boston, São Paulo, and Jintan are the operating form of that strategy, not just points on a map. If global movement of radioactive materials becomes harder, a geographically redundant network becomes more valuable.

Horizontal competitor analysis

The right starting judgment is that there is no perfect listed comparable. Eckert & Ziegler combines a regulated isotope-supply franchise, industrial radioactive sources, generator products, CDMO and engineering capability, and smaller brachytherapy and ophthalmology activities in one quoted vehicle. Most listed peers cover only one slice, so investors usually triangulate rather than compare directly. The best public reference set is a mixed group: Telix Pharmaceuticals as a radiopharma company building its own supply chain; Lantheus as a commercially successful nuclear-medicine company with strong imaging economics; BWX Technologies as a broader nuclear infrastructure group with a medical-isotope adjacency; and Novartis as the large-cap owner of radioligand brands and global commercialization muscle. None is a clean peer, but together they show where Eckert & Ziegler sits in the profit chain.

Telix became a commercial radiopharma platform. Its 2025 results showed strong revenue growth, and the market still values it on the possibility that commercialization plus pipeline optionality can compound for years. Customers pick Telix because it owns branded products and clinical/commercial upside, not because it is the safest infrastructure provider. The contrast with Eckert & Ziegler is stark. Telix is closer to the patient and the drug; Eckert & Ziegler is closer to the enabling layer. Telix can earn much more if its products win, while Eckert & Ziegler can still earn good returns even if several customers share the market, so long as they all need isotopes, purification, or manufacturing support. That is why Telix carries a much richer thematic premium but also a more clinical and regulatory risk-heavy profile.

Lantheus became a commercial diagnostics and radiopharma company with sharper product concentration. Its 2025 revenue was $1.54 billion, and Q1 2026 revenue was $377.3 million. Customers pick Lantheus because it commercialized high-demand nuclear-imaging products at scale, especially in prostate cancer imaging. The market gives Lantheus a healthier earnings multiple than a mature medtech supplier because commercialization is proven. Yet even here the comparison helps Eckert & Ziegler more than it hurts it. Lantheus depends heavily on branded product execution. Eckert & Ziegler is a supplier and enabler to multiple developers and manufacturers. If the radiopharma market broadens beyond a few winners, that positioning can be steadier than a single-product commercial story.

BWX Technologies is useful as a reminder that nuclear capability can command a premium even when the business mix is broader and more defense-oriented. Its 2025 results showed $574.3 million of adjusted EBITDA and strong cash generation. Customers choose BWXT for heavy nuclear engineering and long-duration government-linked contracts, not for radiopharma specialization. The company is not a direct commercial competitor in most of Eckert & Ziegler's growth lanes; it is an ecosystem reference point, proof that scarce nuclear know-how and manufacturing discipline can support a substantial public-market valuation. Compared with BWXT, Eckert & Ziegler is smaller, more specialized, and more exposed to healthcare innovation rather than government budgets.

Novartis plays a different role entirely. It is not a peer for valuation. It is the most visible proof that radioligand therapy is commercially important enough for top-tier pharma to invest, acquire, and defend supply. Customers (physicians, payers and health systems) choose Novartis because it owns approved, clinically validated therapies and global commercialization capabilities. For Eckert & Ziegler, Novartis is both customer-adjacent and competitive context. If large pharma internalizes more of the isotope chain, suppliers may lose some pricing power. If large pharma decides that supply redundancy matters, specialist suppliers may become more valuable. That balance is not settled.

Ecologically, Eckert & Ziegler is a niche infrastructure player with unusually good positioning: neither the end-market champion nor the low-value toll collector. Its real gap in the industry is that many radiopharma developers need a partner that can provide isotope access, downstream purification, handling, manufacturing support, and logistics without forcing them to build the whole chain internally before proof of concept. That gap has widened as clinical activity has expanded faster than isotope and manufacturing capacity. The company draws profit from three directions at once: industrial-source incumbency, generator and isotope sales, and outsourced development and manufacturing work. The parties most likely to take its profit pool are not other mid-caps with the same structure. They are large pharma internalization efforts, ambitious private isotope suppliers, and well-funded integrated radiopharma firms.

Current fundamentals and bull-bear divergence

The last four reported periods show a business that is still moving in the right direction, but with enough lumpiness to keep the stock from earning a simple "quality growth" multiple. In H1 2025, revenue rose to €148.8 million and adjusted EBIT to €35.4 million, with Medical margin benefiting from high-margin sales and a €9 million cash inflow from the Chinese joint venture Qi Kang. By 9M 2025, revenue had reached €224.1 million and adjusted EBIT €50.8 million. Full-year 2025 landed at €312.0 million of revenue and €77.7 million of adjusted EBIT, just short of the original around-€320 million sales target but with the group clearly stepping through the €300 million threshold for the first time. Q1 2026 then produced €72.9 million of revenue, €16.0 million of adjusted EBIT and €10.4 million of net profit, while keeping the full-year outlook unchanged.

The most important detail inside Q1 2026 was not the 7% revenue increase by itself. It was where the pressure and strength showed up. Medical external revenue rose to €41.5 million from €34.4 million, even though Q1 2025 had included €5.0 million of license revenue and Q1 2026 had none. Management also noted that the prior-year quarter was hurt by cyberattack-related delays in gallium-generator deliveries, which were later recovered in Q2 2025. That means the reported year-on-year comparison is not perfectly clean. Even so, Medical adjusted EBIT rose to €14.0 million and gross margin improved to 54%. Isotope Products, by contrast, saw external revenue fall 7% to €31.5 million and adjusted EBIT drop to €2.9 million as gross margin fell from 44% to 40% on weaker mix. The current business is therefore a tale of two segments: Medical is carrying the growth story; Isotope Products remains the ballast, but can also dilute quarterly excitement.

The market is trading roughly three ideas at once right now. First, it is trading isotope-supply scarcity, especially around actinium-225 and lutetium-177. Second, it is trading whether Eckert & Ziegler's CDMO and generator businesses can turn that scarcity into sustained margin expansion rather than one-off license spikes. Third, it is trading capital-market taste: investors want exposure to radiopharma, but after the 2025 run-up they are less willing to pay any price for enabling stories that still guide to low-single-digit near-term growth. The current share price is therefore a blend of real fundamentals and a partially deflated theme premium.

The bull case rests on evidence, not aspiration. Medical already earns much more profit than Isotope Products on only moderately higher revenue. Q1 2026 showed that Medical grew even without license revenue. The company has public, named agreements across several payloads and service layers, and is broadening geographic production and manufacturing capacity. The balance sheet is strong enough to finance further growth without equity dilution pressure. If that set of facts continues, the market can eventually treat the company less like a miscellaneous German mid-cap and more like a specialized infrastructure asset in radiopharma.

The bear case also rests on evidence. The company's own 2026 guidance is still for only about €320 million of revenue and about €80 million of adjusted EBIT, which is modest. Q1 2026 saw clear weakness in Isotope Products. High-margin license revenue is useful, but management explicitly says such revenue is asymmetrically distributed through the year and cannot be extrapolated from interim figures. Public disclosures still do not provide enough detail on current isotope capacity, contract pricing, or customer concentration for outside investors to underwrite a very aggressive long-term growth curve. And the cyberattack in early 2025 was a reminder that even high-quality niche suppliers are exposed to ordinary operational shocks.

The sharpest current disagreement, therefore, is about how much investors should pay before the next level of proof arrives, not about whether the company is good. Bulls think the proof is already embedded in the Medical segment margin and in the growing agreement list. Bears think the missing proof is contractual and quantitative: volumes, visibility and economics. Until those are more visible, the stock will probably continue to trade in a zone where fundamentals are respectable but thematic conviction fades in and out.

Valuation analysis

Historically, today's valuation is a long way from the stock's most excited periods. The company's re-rating in 2021 and the 2024–2025 radiopharma enthusiasm phase both carried stronger narrative momentum than the current setup. By mid-2026, the stock was near the lower end of its 52-week range, with a headline P/E around 18x and a dividend yield around 1.5%. That says the market has already removed a meaningful amount of thematic heat. It does not say the stock is formally cheap. Cheapness depends on whether investors believe the company can move from guided 3% growth to a sustainably faster medium-term path once the current investment cycle bears fruit.

Peer valuation is supportive but not decisive. Compared with Telix, which still reflects platform and pipeline optionality, Eckert & Ziegler is much cheaper. Compared with Lantheus, it sits on a lower multiple despite cleaner balance-sheet features and less product concentration, because Lantheus has already proven large-scale commercial execution. Compared with BWXT, it is cheaper on earnings and far smaller, but the business mix is too different for direct multiple transfer. The right conclusion is not that Eckert & Ziegler is cheap because more thematic peers are expensive. The right conclusion is that the market still prices it as a specialist supplier with growth potential, not as a pure radiopharma winner.

The cash-flow passthrough is better than many thematic healthcare names. Over 2021–2025, operating cash flow averaged roughly 1.5 times net income. Recent capex has simply turned clearly expansionary, which is not a sign of weak earnings quality in aggregate. Management repeatedly described investment focuses in Dresden-Rossendorf, Berlin-Buch, São Paulo and Wilmington, and pointed to new laboratory and production infrastructure linked to generators and actinium scale-up. That suggests total capital spending has included a meaningful growth component rather than just maintenance. A reasonable owner-earnings treatment is therefore to deduct only a modest maintenance capex estimate (roughly €8 million to €10 million a year) from normalized earnings, not the full recent expansion spend. On that basis, 2025 owner earnings are roughly €39 million to €41 million, or about €0.63 to €0.65 per share, implying an owner-earnings P/E of about 22x to 23x at the current price. That is above the headline P/E but not by more than 30%, so the valuation can still be framed mainly on earnings and EV/EBIT, with owner earnings used as a check rather than a full replacement metric.

The absolute valuation below uses 2028 as the anchor year. That is long enough for current capacity projects and supply agreements to matter, but not so long that the exercise becomes fantasy. It is a research framework, not investment advice.

Using the midpoints of those scenarios, fair values come out near €14.8 in the conservative case, €17.0 in the base case, and €20.1 in the optimistic case. With the stock at €14.43, the market is roughly pricing the conservative-to-low-base zone: it is giving the company credit for quality and net cash, but not for a dramatic radiopharma breakout.

Expectation-gap analysis points to a narrow set of numbers. The market no longer needs another broad presentation about radiopharma tailwinds. It needs proof on three items: Medical segment revenue growth excluding license timing, segment margins once license/lumpiness is normalized, and disclosed progress in actinium and CDMO scale-up. The next earnings releases matter less for headline revenue and more for whether Medical keeps widening the gap over Isotope Products. If the company can post another few quarters where Medical strength offsets license variability and Isotope Products merely stabilizes, the base-case valuation can rise. If Medical growth depends too visibly on lumpy license accruals, the multiple can stay stuck.

The margin-of-safety recheck is sobering. At €14.43, the stock is only slightly below the conservative fair value around €14.8, which means the margin of safety is minimal. The most fragile assumption in the base case is margin persistence in Medical, not revenue growth. If that assumption is cut to 70% of the planned uplift, the base-case fair value falls back toward roughly €15.0–15.5. If earnings are flat for the next three years and the stock simply holds roughly the current multiple, annualized return would be driven mostly by the 1.5% dividend yield and would likely sit below the current German 10-year Bund yield around 3.1%. On that test, there is no meaningful margin of safety at today's buy price. This is a good company at a fairer price than a year ago, but not yet at a clearly generous one.

Risk analysis

The biggest business risk is that the Medical segment's apparent inflection turns out to be more mix-driven and lumpier than the market hopes. This is a medium-probability, high-impact risk. The observable indicator is Medical revenue growth excluding license revenue and the gross-margin line in that segment. The transmission path is straightforward: if generator sales, CDMO activity and isotope supply do not scale steadily enough, group earnings stay dependent on uneven license accruals, investors stop paying even the current mid-teen earnings multiple, and the stock drifts toward a pure supplier valuation. Management has already hinted at this sensitivity by noting that license revenues are planned for the year but distributed asymmetrically over reporting periods.

The second risk is that actinium-225 and broader isotope-supply expansion produce less economic rent than the market narrative suggests. This is also medium probability and high impact. The company has demonstrated technical progress and public agreements, but it has not disclosed the detailed capacity, utilization, or contract-pricing specifics that would let investors judge how much scarcity rent will actually be captured. The observable indicators are named multi-year supply announcements, GMP qualification progress, and evidence that Medical margins remain high even as basic isotope volumes scale. If scarcity rents fade quickly because more capacity comes online or customers diversify supply, the premium part of the growth thesis softens.

A third risk is operational. The February 2025 cyberattack did not become a financial disaster, but it did temporarily disrupt digital processes and generator deliveries, with effects management said extended into subsequent periods. In a business that coordinates regulated manufacturing, logistics, documentation and customer supply, ordinary IT resilience matters more than in a less regulated industry. The probability is medium, the impact medium, and the indicator is any repeat of production or delivery interruptions. The transmission path runs through delayed shipments, weaker quarterly comparisons, and a renewed market fear that a high-quality niche supplier can still stumble on unglamorous basics.

The fourth risk is governance and related-party texture. The company is not in visible governance distress, but founder influence remains strong, and related-party leases and consulting arrangements exist. Probability is low to medium and impact medium. The key indicator is any increase in related-party dealings, weaker board independence, or capital-allocation moves that benefit control more than minority holders. The transmission path would be through valuation discount rather than immediate earnings damage. Good businesses can still trade cheaply for years if governance trust is incomplete.

The final major risk is valuation compression without business deterioration. This sounds softer than the others, but for public-market investors it matters. The stock today is not expensive enough to scream bubble, yet it still reflects some belief in higher-quality future growth. If rates stay higher, risk appetite fades, or radiopharma-platform enthusiasm cools further, the multiple can compress even if operations remain sound. Given the German 10-year Bund yield around 3.1%, a stock offering only modest near-term growth and limited dividend yield does not have a huge valuation cushion. The indicator is not one quarterly number. It is the market's willingness to keep rewarding specialized healthcare infrastructure at more than plain-industrial multiples.

Catalysts and tracking indicators

Positive catalysts are fairly concrete. Another quarter in which Medical grows strongly without meaningful license contribution would be powerful evidence that the segment's profit mix is becoming more repeatable. New public supply or CDMO agreements that disclose multi-year scope, geography or payload breadth would help narrow the information gap on future volume visibility. Additional regulatory wins such as geography expansion for GalliaPharm or further GMP-related milestones in actinium processing would also matter because they convert technical readiness into revenue addressability. The opening of the Jintan site and the lead-212 partnership with Thor Medical show the sort of incremental platform-building the market wants to see.

Negative catalysts are just as clear. A guidance cut would matter more than a modest quarterly miss because 2026 guidance is already restrained. Another quarter with weak Isotope Products mix and no offset from Medical would raise fears that only one side of the business is working. A visible slowdown in generator sales, loss of a supply agreement, or evidence that actinium scale-up is slower than expected would likely matter more than small fluctuations in group sales. So would any renewed cyber or operational outage affecting deliveries.

The dashboard matters because each item maps to a different part of the thesis. Medical margin tells you whether the higher-quality growth story is real. Isotope Products margin tells you how much drag the legacy base might create. Cash conversion tells you whether reported earnings are keeping financial substance. Net financial position captures whether the company is funding growth from strength or from balance-sheet stretch. Agreement cadence is a crude but useful public proxy for commercial relevance in radiopharma, though investors should remember that public announcements are not the same as signed economics. The next scheduled earnings report is the H1 2026 release on 2026-08-13.

Cross-synthesis summary

Vertically, Eckert & Ziegler has proven one thing unusually well: it can turn awkward, regulated, low-glamour capabilities into a durable listed business, then reposition that business when the industry around it changes. The company did not invent radiopharma. It spent decades learning how to handle radioactive materials safely, legally and at scale, then found that those old capabilities became newly valuable when oncology drug development began leaning hard into radionuclides. That distinction matters because it separates durable capability from fortunate timing. The radiopharma boom helped. The company was able to help itself because it already knew how to do the fussy parts that newcomers usually underestimate.

Past success came from a combination of management capability and era tailwinds, with luck helping at the margin. The strategic judgment to consolidate adjacent isotope assets, keep multi-jurisdictional permits and logistics capabilities alive, and then simplify the portfolio around isotopes looks good in hindsight. The radiopharma funding wave and large-pharma interest from the late 2010s onward were external gifts to anyone positioned to serve them. Many companies had the tailwind. Fewer had both the installed technical base and the willingness to prune mismatched assets such as the HDR business and the embedded Pentixapharm development story. Those success factors are still present today, though the external tailwind is no longer enough on its own to power the stock. Now the company needs execution, not just exposure.

Horizontally, the real advantage over competitors is not that Eckert & Ziegler is larger or more fashionable. It is that it inhabits an attractive niche between raw isotope production and branded therapy ownership. Telix and Lantheus sit closer to commercial products. Novartis sits at the therapy giant end. BWXT sits in broader nuclear infrastructure. Eckert & Ziegler occupies the middle: the specialist with enough regulatory, purification, handling, logistics and manufacturing depth to matter to many customers at once. That is a good place to be in an industry where many participants would rather outsource the hard radioactive parts than become experts in them. The weakness is that this middle position makes it harder for the market to assign a clean multiple. The company is better than a plain supplier, but less explosive than a successful therapy owner.

The current valuation partly rewards past success and partly prespends on future success, but not aggressively. At about 9.8x forward EV/adjusted EBIT and about 18x trailing earnings, the stock is no longer priced like a narrative peak. It is also not priced for stagnation. The market is giving Eckert & Ziegler some credit for higher-quality growth, some credit for its cash-rich balance sheet, and limited credit for a dramatic radiopharma breakthrough. That valuation stance is rational. The missing piece is visibility. If the company disclosed or demonstrated better multi-year evidence on isotope and CDMO economics, the stock could deserve a firmer premium. As things stand, investors are still being asked to infer too much.

What the market is most likely misjudging is not the existence of the opportunity. It is the shape of the profit path. On the bullish side, some investors still underestimate how much of the moat is already in place and how difficult it is to replicate the downstream regulated stack. On the bearish side, some investors underrate the fact that Medical profitability is not a theory anymore. It is already visible. But the market at large still lacks enough disclosed evidence to decide whether 2025–2026 is the start of a durable higher-growth period or simply a profitable transition with occasional license windfalls. Until that is clearer, the stock will probably continue to trade like a good company whose best story is only partly underwritten by public data.

For the next year, the most critical variable is Medical margin quality without license help. For the next three years, it is whether actinium, lutetium, generators and CDMO services produce visible, repeatable scale rather than a sequence of promising announcements. For five years, the crucial question is strategic role: does Eckert & Ziegler become one of the standard infrastructure partners in radiopharma, or do larger players internalize enough of the chain to cap supplier economics? The company becomes a better investment under two conditions: first, if the stock falls toward a true margin-of-safety zone around the low-€11s; second, if the company proves through another year or two of results that Medical can compound without relying on especially favorable timing. An investor should revisit the thesis if Medical gross margin drops structurally, if net cash weakens without a compelling acquisition rationale, if new partnership flow dries up, or if the company starts publishing evidence that large customers are bringing more isotope processing in-house.

Bull and bear reasons

• Medical generated €51.1 million of adjusted EBIT on €171.0 million of external revenue in 2025, showing that the profit center has already shifted toward higher-margin radiopharma-related activities.

• Q1 2026 revenue rose 7% and Medical margins improved even though there was no license revenue in the quarter, which suggests the underlying engine is stronger than a single lumpy line item.

• The company ended 2025 with €115.2 million of net financial position and still showed a strong cash position in Q1 2026, giving it room to expand without balance-sheet stress.

• Publicly disclosed agreements across Lu-177, Ac-225, Pb-212 and CDMO services show that customers are using Eckert & Ziegler for multiple payloads and stages of the value chain rather than for one narrow product.

• 2026 guidance still implies only about 3% revenue growth and about 3% adjusted EBIT growth, so the near-term reported growth profile is modest for a business exposed to a hot theme.

• Isotope Products weakened in Q1 2026, with gross margin falling to 40%, showing that one major segment can still offset part of Medical's progress.

• License revenue is explicitly uneven through the year, which makes the quality and repeatability of high-margin Medical earnings harder to judge from interim results.

• Public disclosures still do not give enough detail on current isotope capacity, contract pricing or customer concentration to justify a high-confidence long-term growth model.

• Founder influence and related-party arrangements are manageable but real, which supports some governance discount for minority shareholders.

Pre-mortem

A plausible three-year failure script starts with margin disappointment rather than outright revenue collapse. Suppose that by 2027–2028 the Medical segment still grows, but license revenue becomes negligible, actinium scaling adds less profit than expected, and generator/CDMO growth does not fully replace the high-margin mix benefit seen in 2025. Medical gross margin slips from the low-50s back toward the high-40s, group adjusted EBIT stalls near the low-€70 millions, and the market stops granting a specialized-growth multiple. If EV/adjusted EBIT compresses from roughly 10x forward today to 7–8x on flat earnings, the equity could reasonably trade in the €8–10 range, a drawdown of roughly 30%–45% before dividends.

A second script is more specific to industry structure. Imagine that by 2028 larger radiopharma players and better-capitalized isotope specialists secure enough upstream and downstream capacity that suppliers lose scarcity pricing sooner than expected. Eckert & Ziegler would still have a sound business, but not an unusually advantaged one. Revenue might continue to grow modestly while margin expansion stops, the market would re-rate the company toward a plain industrial-healthcare specialty supplier, and the share price could halve from a more optimistic entry point even without a crisis. The danger is not bankruptcy. The danger is that a good business turns out cheaper than thematic investors expected.

Final research conclusion

Eckert & Ziegler is a better business than its old market label implies. The company has spent decades building a regulated isotope-handling, purification, logistics and manufacturing network that suddenly matters far more because radiopharmaceutical oncology now needs exactly those capabilities. The 2025 and Q1 2026 numbers show the transition already happening in the income statement: Medical is the real profit engine, margins have improved for reasons management can name, and the balance sheet is strong enough to fund expansion without financial strain. That is the good news. The harder truth is that the public disclosures still leave too much of the next leg of growth to inference. Investors can see named agreements and milestone progress, but they cannot yet clearly see the long-duration economics.

At the current price, the stock looks fairer than it did during its more euphoric phase, but it still does not offer a convincing margin of safety for new money. That does not make it unattractive. It makes it selective. Existing shareholders with a multi-year horizon have a reasonable case to stay with the story, because the company's strategic position is sound and the valuation is no longer inflated. New buyers should be more patient. The main thing that would change this judgment would be either a cheaper entry point in the low-€11s or a fuller year of evidence that Medical can keep compounding without leaning on especially favorable license timing.

【Company-profile scores】

• Fundamental quality: high
• Growth: medium
• Moat: medium
• Financial soundness: strong
• Management credibility: medium
• Valuation attractiveness: low
• Risk level: medium
• Suitable investor type: long-term growth

【Investment rating】

• Rating: Hold
• One-line thesis: A financially strong isotope specialist is becoming a better radiopharma infrastructure asset, but the current price still leaves little margin of safety versus disclosed growth.
• Three price signals:
  • 【Ideal Buy Price】11.0–11.8 EUR Basis: at least a 20% margin of safety below the conservative fair-value zone implied by the 2028 conservative scenario.
  • Acceptable hold price: 13.8–18.6 EUR
  • Clearly overvalued price: above 20.7 EUR
• Current-price classification: acceptable hold
• Whether to wait for a better price: yes. A new purchase becomes attractive below roughly €11.8, or earlier if two more quarters show Medical can sustain high margins without meaningful license contribution. The opportunity cost of waiting is missing a re-rating driven by faster-than-guided execution in isotopes and CDMO.
• Target holding horizon: 3–5 years
• Expected annualized return: conservative about 1%–2%; base about 6%–8%; optimistic about 11%–13%
• Max-loss risk: roughly 40%–50% in the pre-mortem case, triggered by weaker Medical margin quality, fading scarcity economics, and a re-rating toward plain supplier multiples
• Reassessment-trigger signals:
  • if Medical gross margin falls below 48% for two consecutive quarters
  • if Isotope Products gross margin stays below 39% for two consecutive quarters
  • if net financial position drops below €70 million without clearly accretive M&A
  • if 2026–2027 guidance is cut while Medical still relies on lumpy license timing
  • if the cadence of meaningful isotope or CDMO partnership announcements materially slows for a year

【Valuation Range】

• current: 14.43 (close as of 2026-07-14)
• bear (conservative · ideal buy zone): [11.0, 11.8]
• base (fair · acceptable hold zone): [13.8, 18.6]
• bull (optimistic · above the clearly-overvalued line): [20.7, 23.0]

Key data tables

The business meaning inside this table is more important than the table itself. Revenue compounded strongly across all five years, but profit quality visibly improved only after portfolio simplification and Medical mix gains became large enough to outweigh the drag from investment and lower-margin activities. The surge in net financial position by 2024–2025 is what gives management room to keep building capacity without financial strain.

† Telix reports in AUD and combines commercial radiopharma growth with pipeline investment; it is included as a reference point rather than a direct comparable. The table shows why no single peer works. Eckert & Ziegler is much smaller and cheaper than the radiopharma end-market winners, but also much more focused on the enabling layer than on owning blockbuster drugs.

Research uncertainties

• The company does not publicly disclose enough current detail on Lu-177 and Ac-225 capacity, utilization, contract duration, or pricing to model supply economics with high confidence.
• Public partnership announcements are informative about relevance, but they do not tell investors how much revenue or margin each agreement will contribute.
• The exact split between maintenance capex and growth capex is not stated directly in recent filings; the owner-earnings estimate therefore rests on a reasoned but still approximate maintenance-capex assumption.
• Some market-data providers handle the post-August-2025 split inconsistently, so long-run per-share history should be treated carefully; this report relies on company-restated, split-adjusted figures wherever possible.
• Current capital-market narrative around radiopharma can change quickly if large pharma internalizes more supply-chain steps or if new capacity comes online faster than expected.

Sources

Primary company materials formed the backbone of this report: Eckert & Ziegler's annual reports for 2021, 2022, 2023, 2024 and 2025; the Q1 2026, H1 2025 and 9M 2025 reports; the company history, management, investor share, corporate-governance and financial-calendar pages; and company/EQS press releases on partnerships, the stock split, cyberattack recovery, Ac-225 scale-up, and the Jintan site.

Market and macro reference points came from current quote pages and official rate sources: EUZ share data from finance sites for the 2026-07-14 close and valuation snapshot, the ECB's euro-dollar reference rate for 2026-07-14, and German 10-year Bund yield references from current market data pages.

Industry context and peer framing came from Reuters, the Financial Times, and primary peer disclosures from Telix, Lantheus, BWX Technologies and Novartis.

Other tickers mentioned

• TLX.AU: partial peer and radiopharma reference point for commercialization plus supply-chain build-out
• LNTH.US: partial peer showing how nuclear-medicine product commercialization can earn a higher market multiple
• BWXT.US: broader nuclear infrastructure reference point for the market value of regulated nuclear capability
• NVS.US: end-market benchmark for radioligand commercialization and large-pharma supply-chain strategy
• SHL.XETRA: referenced as part of the imaging ecosystem and source-related quality-control context
• BCYC.US: customer-partner example showing Eckert & Ziegler’s role in isotope supply and radiopharma manufacturing

This report is based on public information and does not constitute investment advice. Markets carry risk; invest with caution.